Your browser is no longer supported. Please, upgrade your browser.
DERM Dermira, Inc. daily Stock Chart
DERM [NASD]
Dermira, Inc.
Index- P/E- EPS (ttm)-4.37 Insider Own0.95% Shs Outstand54.70M Perf Week0.11%
Market Cap1.03B Forward P/E- EPS next Y-4.26 Insider Trans- Shs Float43.84M Perf Month-2.11%
Income- PEG- EPS next Q-1.39 Inst Own93.62% Short Float6.66% Perf Quarter146.06%
Sales82.87M P/S12.37 EPS this Y20.10% Inst Trans- Short Ratio1.23 Perf Half Y119.04%
Book/sh0.27 P/B70.49 EPS next Y-1.20% ROA- Target Price21.50 Perf Year147.04%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range5.25 - 19.48 Perf YTD23.68%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-3.75% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low257.14% ATR0.15
Employees333 Current Ratio- Sales Q/Q1508.50% Oper. Margin- RSI (14)72.42 Volatility0.19% 0.50%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.45 Prev Close18.75
ShortableNo LT Debt/Eq- EarningsFeb 25 AMC Payout- Avg Volume2.36M Price18.75
Recom2.70 SMA20-0.14% SMA5013.59% SMA20080.42% Volume0 Change0.00%
Jun-06-19Upgrade Mizuho Neutral → Buy $17 → $14
Mar-25-19Reiterated Needham Buy $16 → $22
Feb-22-19Initiated SVB Leerink Outperform $20
Feb-14-19Initiated H.C. Wainwright Buy $13
Jan-17-19Upgrade Raymond James Underperform → Mkt Perform
Nov-20-18Resumed Guggenheim Buy $20
Mar-06-18Downgrade Guggenheim Buy → Neutral
Mar-05-18Downgrade Mizuho Buy → Neutral $39 → $9
Mar-05-18Downgrade Mizuho Buy → Neutral
Dec-12-17Reiterated Mizuho Buy $43 → $39
Dec-06-17Initiated Guggenheim Buy $30
Nov-07-17Reiterated Needham Buy $46 → $43
Jun-30-17Initiated Evercore ISI Outperform $48
May-25-17Reiterated Mizuho Buy $42 → $40
Mar-31-17Initiated Mizuho Buy $42
Mar-16-17Initiated Raymond James Underperform
Jun-02-16Reiterated Needham Buy $42 → $46
May-11-16Reiterated Needham Buy $38 → $42
Jan-08-16Reiterated Needham Buy $33 → $38
Dec-18-15Upgrade Citigroup Neutral → Buy
Feb-23-20 05:23PM  Largest Insider Trades of the Week GuruFocus.com
Feb-20-20 08:55AM  Lilly Completes Acquisition of Dermira PR Newswire
Feb-07-20 01:04PM  (DERM) Alert: Johnson Fistel Continues Investigation of Proposed Sale of Dermira, Inc. for $19.30 GlobeNewswire
Feb-05-20 01:30PM  INVESTOR ALERT: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - LOGM, DERM, HXL ACCESSWIRE
Feb-04-20 08:00PM  CSFL, DLPH, DERM, and HXL SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers GlobeNewswire
Jan-30-20 02:20PM  SHAREHOLDER ALERT: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - HXL, DERM, HABT ACCESSWIRE
10:38AM  Lilly (LLY) Q4 Earnings and Sales Top Estimates, Stock Up Zacks
09:59AM  SHAREHOLDER ALERT: WeissLaw LLP Reminds CBB, HABT, DERM, and MFSF Shareholders About Its Ongoing Investigations GlobeNewswire
Jan-29-20 07:26PM  Lifshitz & Miller LLP Announces Investigation of AquaVenture Holdings Limited, CenterState Bank Corporation, Dermira, Inc., The Habit Restaurants, Inc., Hexcel Corporation, LogMeIn, Inc., Telaria, Inc, and TiVo Corporation PR Newswire
12:33PM  SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders HABT, DERM, HXL, PRMW GlobeNewswire
Jan-28-20 08:00PM  PRMW, DERM, HABT, and HXL SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers GlobeNewswire
Jan-27-20 08:16AM  Lilly (LLY) to Report Q4 Earnings: What's in the Cards? Zacks
Jan-24-20 04:46PM  SHAREHOLDER ALERT: WeissLaw LLP Reminds HABT, DERM, and MFSF Shareholders About Its Ongoing Investigations GlobeNewswire
Jan-20-20 11:15AM  MERGER ALERT - INST, DERM, and PRMW: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies ACCESSWIRE
09:00AM  SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders CBB, HABT, DERM, IBKC GlobeNewswire
Jan-15-20 09:00PM  DERM, CRCM, LOGM, and WAAS SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts GlobeNewswire
02:25PM  Edited Transcript of DERM earnings conference call or presentation 5-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
01:19PM  Bragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of Dermira, Primo Water, Hexcel, and Pope Resources on behalf of Stockholders and Encourages Investors to Contact the Firm PR Newswire
11:16AM  Moore Kuehn, PLLC Encourages PRMW, DERM, CBB, and HABT Investors to Contact Firm PR Newswire
Jan-14-20 11:13AM  Big Merger Deals Are Missing at Health Conference. Heres Why. Barrons.com
Jan-13-20 06:48PM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Dermira, Inc. - (Nasdaq:DERM) ACCESSWIRE
12:33PM  Biotech Stocks Slip on Lack of Deals at JPMorgan Conference Bloomberg
11:30AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Dermira, Inc. to Eli Lilly and Company is Fair to Shareholders ACCESSWIRE
09:08AM  Lilly to Buy Dermira for $1.1B, Add Phase III Eczema Candidate Zacks
Jan-11-20 09:30AM  SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - CBB, HABT, DERM ACCESSWIRE
Jan-10-20 06:00PM  Biotechs punch up talking points leading into big Union Square conference American City Business Journals
04:33PM  Eli Lilly Made a Deal for Dermira. The Biotechs Stock Price Shows Investors Expect More. Barrons.com
03:23PM  SHAREHOLDER ALERT: WeissLaw LLP Investigates Dermira, Inc. PR Newswire
01:23PM  SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of DERMIRA, INC. - DERM PR Newswire
01:10PM  DERMIRA, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout ACCESSWIRE
12:28PM  DERMIRA MERGER INVESTIGATION: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Dermira, Inc. is Fair to Shareholders; Investors are Encouraged to Contact the Firm DERM GlobeNewswire
12:13PM  ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Dermira, Inc. PR Newswire
10:43AM  Eli Lilly to add eczema drug with $1.1 billion deal for Dermira Reuters
10:43AM  Eli Lilly, Apple, Yum! Brands, Nintendo: Companies to watch Yahoo Finance
09:50AM  Lilly Says Its Buying a Biotech With a Dermatitis Drug. Investors Have Other Ideas. Barrons.com
09:33AM  The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences Zacks
09:03AM  Benzinga Pro's Top 5 Stocks To Watch For Fri., Jan. 10, 2020: LLY, JPM, SRNE, ELAN, TWTR Benzinga
08:36AM  S&P 5,000? Why one fund manager says that milestone may be reached sooner than you would expect MarketWatch
08:35AM  (DERM) Alert: Johnson Fistel Investigates Proposed Sale of Dermira, Inc.; Is $19.30 a Fair Price? PR Newswire
07:28AM  Eli Lilly Reports Deal To Buy Dermira For $1.1B Benzinga
06:42AM  Eli Lilly to buy Dermira in a deal valued at $1.1 billion MarketWatch
06:30AM  Lilly Announces Agreement to Acquire Dermira PR Newswire
04:44AM  Eli Lilly to Buy Skin Treatment Company Dermira for $1.1 Billion TheStreet.com
03:38AM  Pre-market Movers - Eli Lilley, Boeing in View Investing.com
Jan-09-20 06:19AM  Buy Multibagger Stocks as Odds of a Rally Are High in 2020 Zacks
Jan-08-20 11:16AM  Pacira's (PCRX) Exparel Meets Key Goals in C-Section Study Zacks +13.62%
Jan-06-20 10:00AM  Moving Average Crossover Alert: Dermira Zacks
07:31AM  Will Dermira Continue to Surge Higher? Zacks
Dec-19-19 05:51PM  4 More Biotechs With Blockbuster Potential GuruFocus.com +5.85%
Dec-10-19 04:05PM  Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +10.12%
08:30AM  Dermira Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis Business Wire
07:47AM  Is Dermira (NASDAQ:DERM) Using Debt In A Risky Way? Simply Wall St.
Dec-08-19 07:29PM  Heres What Hedge Funds Think About Dermira Inc (DERM) Insider Monkey
Nov-27-19 04:05PM  Dermira to Participate in December Investor Conferences Business Wire
Nov-14-19 04:05PM  Dermira Presents New Scientific Research Findings from the Lebrikizumab Program at Leading International Itch Conference Business Wire -6.92%
Nov-13-19 04:05PM  Dermira Elects Halley E. Gilbert to its Board of Directors Business Wire
Nov-11-19 04:10PM  Dermira to Participate in the Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day Business Wire
Nov-08-19 04:05PM  Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +18.08%
10:18AM  Short Seller Scores Big Win as Tiny Biotech Stock Sinks 72% Bloomberg
10:04AM  The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co Zacks
08:00AM  Pharma Sector Tops in October: Best ETFs & Stocks Zacks
Nov-07-19 09:17AM  Trade Deal Delay Unlikely to Hit U.S. Healthcare: 4 Picks Zacks
06:07AM  3 Biotech Stocks Needham Expects to Double in the Next 12 Months TipRanks
Nov-06-19 10:36AM  Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales Zacks
Nov-05-19 07:15PM  Dermira (DERM) Reports Q3 Loss, Tops Revenue Estimates Zacks -5.65%
04:05PM  Dermira Reports Third Quarter 2019 Financial Results and Provides Corporate Update Business Wire
Oct-29-19 04:05PM  Dermira to Report Third Quarter 2019 Results and Host Conference Call on Tuesday, November 5, 2019 Business Wire +6.67%
Oct-25-19 09:03AM  Did You Manage To Avoid Dermira's (NASDAQ:DERM) Devastating 79% Share Price Drop? Simply Wall St.
Oct-18-19 10:23AM  These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year American City Business Journals +25.83%
Oct-17-19 04:05PM  Dermira Presents Data From Phase 2b Study of Lebrikizumab in Patients With Atopic Dermatitis at Fall Clinical Dermatology Conference Business Wire
Oct-14-19 10:28AM  Aclaris Divests Rhofade to EPI Health for $55M, Shares Up Zacks -6.68%
Oct-10-19 09:57AM  Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study Zacks
08:30AM  Dermira to Present Data from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis at Fall Clinical Dermatology Conference Business Wire
Oct-09-19 08:30AM  Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis Business Wire
Oct-08-19 04:05PM  Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire -6.23%
Sep-26-19 04:05PM  Dermira to Participate in the 2019 Cantor Global Healthcare Conference Business Wire -6.73%
Sep-10-19 12:24PM  How Much Are Dermira, Inc. (NASDAQ:DERM) Insiders Spending On Buying Shares? Simply Wall St. +7.27%
Aug-29-19 04:05PM  Dermira to Participate in Upcoming Investor Conferences Business Wire
Aug-20-19 12:15AM  Dermira Inc (DERM) CEO & Chairman of the Board Thomas G Wiggans Bought $199,998 of Shares GuruFocus.com
Aug-14-19 09:02PM  Edited Transcript of DERM earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-07-19 07:45PM  Dermira (DERM) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM  Dermira Reports Second Quarter 2019 Financial Results and Provides Corporate Update Business Wire
Jul-31-19 04:05PM  Dermira to Report Second Quarter 2019 Results and Host Conference Call on Wednesday, August 7, 2019 Business Wire
Jul-29-19 10:34AM  Earnings Preview: Dermira (DERM) Q2 Earnings Expected to Decline Zacks
Jul-25-19 01:03PM  5 Biotech Stocks to Buy for Blockbuster Potential Kiplinger
Jul-24-19 03:15PM  Should You Be Pleased About The CEO Pay At Dermira, Inc.'s (NASDAQ:DERM) Simply Wall St.
Jul-01-19 09:15AM  Stocks Soar 7% in June Zacks
Jun-25-19 01:30AM  Almirall Exercises its Option with Dermira to License Rights to Lebrikizumab in Europe for Atopic Dermatitis Business Wire
Jun-11-19 04:00PM  Dermira to Present at the Raymond James Life Sciences and MedTech Conference Business Wire -6.06%
Jun-06-19 01:34PM  Dermira Advances on Analyst Upgrade to Buy TheStreet.com
Jun-03-19 10:31PM  Edited Transcript of DERM earnings conference call or presentation 7-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-08-19 03:24PM  Dermira (DERM) Q1 2019 Earnings Call Transcript Motley Fool +6.67%
11:13AM  Did You Manage To Avoid Dermira's (NASDAQ:DERM) Painful 63% Share Price Drop? Simply Wall St.
May-07-19 07:25PM  Dermira (DERM) Reports Q1 Loss, Lags Revenue Estimates Zacks
06:19PM  Dermira: 1Q Earnings Snapshot Associated Press
04:05PM  Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update Business Wire
Apr-30-19 04:05PM  Dermira to Report First Quarter 2019 Results and Host Conference Call on Tuesday, May 7, 2019 Business Wire -5.21%
Apr-25-19 10:34AM  Dermira (DERM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
Apr-17-19 09:15AM  NASDAQ Back Above 8,000 Zacks -6.23%
Apr-08-19 05:06PM  Here's Why Dermira Shot Up 62% in March Motley Fool
Dermira, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older. It also develops lebrikizumab, a novel injectable humanized monoclonal antibody targeting interleukin 13 that is in Phase IIb clinical trial for the treatment of moderate-to-severe atopic dermatitis; and early-stage research and development programs in other areas of dermatology. Dermira, Inc. has a right of first negotiation agreement with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate for the treatment of hyperhidrosis in Japan; an agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab; and a development and commercialization agreement with UCB Pharma S.A. to develop Cimzia for the treatment of psoriasis. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California. As of February 19, 2020, Dermira, Inc. operates as a subsidiary of Eli Lilly and Company.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bald Eagle Acquisition Corp10% OwnerFeb 20Buy18.7540,926,025767,362,969100Feb 20 04:00 PM
Fust Matthew KDirectorDec 24Sale15.003,00045,0005,051Dec 26 04:13 PM
Fust Matthew KDirectorDec 12Sale12.003,00036,0008,051Dec 13 05:13 PM
Fust Matthew KDirectorSep 12Sale8.776,00052,63611,051Sep 16 04:09 PM
Pena Luis C.Chief Development OfficerAug 19Option Exercise0.993,5763,52640,628Aug 19 09:53 PM
WIGGANS THOMAS GCEO & Chairman of the BoardAug 19Buy8.5423,419199,99875,940Aug 19 09:48 PM
Pena Luis C.Chief Development OfficerAug 19Sale8.5423,419199,99817,209Aug 19 09:53 PM
Pena Luis C.Chief Development OfficerAug 15Option Exercise0.008,627041,331Aug 19 09:53 PM
WIGGANS THOMAS GCEO & Chairman of the BoardAug 15Option Exercise0.0025,500065,166Aug 19 09:48 PM
BAUER EUGENE AChief Medical OfficerAug 15Option Exercise0.007,913018,067Aug 19 09:48 PM
Griffith Christopher M.Chief Business & Strategy OffAug 15Option Exercise0.004,473068,438Aug 19 09:48 PM
Lyons-Williams LoriChief Commercial OfficerAug 15Option Exercise0.003,189026,983Aug 19 09:49 PM
GUGGENHIME ANDREWCFOAug 15Option Exercise0.009,975044,378Aug 19 09:48 PM
CRAVES FRED BDirectorJun 12Option Exercise0.003,00006,000Jun 14 05:16 PM
RINGO WILLIAM RDirectorJun 12Option Exercise0.003,00006,000Jun 14 05:15 PM
Sebelius KathleenDirectorJun 12Option Exercise0.003,00006,000Jun 14 05:16 PM
Nunn Jason RaleighDirectorJun 12Option Exercise0.003,00006,000Jun 14 05:16 PM
MCDADE MARKDirectorJun 12Option Exercise0.003,00006,000Jun 14 05:16 PM
Fust Matthew KDirectorJun 12Option Exercise0.003,000017,051Jun 14 05:16 PM
Cohen David EDirectorJun 12Option Exercise0.003,000035,682Jun 14 05:16 PM
Pena Luis C.Chief Development OfficerMay 17Option Exercise0.0025,000041,349May 21 04:03 PM
GUGGENHIME ANDREWCFOMay 17Option Exercise0.0025,000043,048May 21 04:03 PM
Horan ChristopherChief Technical Ops OfficerMay 17Option Exercise0.0026,667029,071May 21 04:04 PM
Lyons-Williams LoriChief Commercial OfficerMay 17Option Exercise0.0030,000034,168May 21 04:03 PM
Griffith Christopher M.Chief Business & Strategy OffMay 17Option Exercise0.0025,000072,610May 21 04:03 PM
BAUER EUGENE AChief Medical OfficerApr 08Option Exercise1.2235,00042,63043,900Apr 09 04:40 PM
BAUER EUGENE AChief Medical OfficerApr 08Sale15.0035,000525,0008,900Apr 09 04:40 PM